uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
(Thomson Reuters ONE) -
Investor and Analyst Breakfast to be Held on Friday, May 12 at 7 a.m. EDT to
Feature Data Presented at Meeting
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 24, 2017 (GLOBE NEWSWIRE)
-- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing
transformative therapies for patients with severe medical needs, today announced
that five abstracts have been accepted for presentation at the American Society
of Gene and Cell Therapy (ASGCT) 20(th) Annual Meeting held in Washington, D.C.,
May 10-13, 2017. Together with their collaborators, members of uniQure's
research and development team will present data focused on progress in re-
administration protocols, gene therapy delivery systems and optimized vector
distribution technologies in two of uniQure's key programs, hemophilia B and
Huntington's disease. An investor and analyst breakfast meeting featuring senior
members of uniQure's research and development team will be held on Friday, May
12 at 7 a.m.
"The data to be presented at the ASGCT meeting demonstrate the development and
validation of uniQure's technologies to improve gene therapy as a therapeutic
approach, and supports our aim to rapidly bring new disease-modifying therapies
to patients with severe genetic diseases," stated Matthew Kapusta, chief
executive officer of uniQure.
Harald Petry, Ph.D., chief scientific officer at uniQure, added, "We are making
strong progress in advancing the preclinical development of AMT-130 in
Huntington's disease, and further enhancing AAV vector technology and the
potential for re-administration protocols, which continue to provide compelling
evidence of our modular platform."
Specific details on uniQure's presentations at ASGCT include:
* Title: Novel AAV Vector Reservoirs: peripheral Blood Cells and Hematopoietic
Progenitors. (collaborator presentation)
Oral Session Title: AAV Vector Biology
Date and Time: Wednesday, May 10, 2017, 10:30 a.m. EDT
Location: Marriott Salon 1
* Title: Circulating Anti-AAV5 Neutralizing Antibody Titers up to 1:1031 Do
Not Affect Liver Transduction Efficacy of AAV5 Vectors in Non-Human
Primates (Poster 198).
Poster Session Title: Immunological Aspects of Gene Therapy and Vaccines I
Session Date and Time: Wednesday, May 10, 2017, 5:30 - 7:30 p.m. EDT
Location: Hall A&B South
* Title: Successful Repeated Hepatic Gene Delivery in Non-Human Primates
Achieved with AAV5 by Use of Immune Adsorption (Poster 395).
Poster Session Title: Immunological Aspects of Gene Therapy and Vaccines II
Session Date and Time: Thursday, May 11, 2017, 5:15 - 7:15 p.m. EDT
Location: Hall A&B South
* Title: AAV5-miHTT Gene Therapy Demonstrates Broad Vector Distribution and
Strong Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
Oral Session Title: Preclinical Progress Towards Therapies for Neurologic
Disorders
Date and Time: Friday, May 12, 2017, 4:30 p.m. EDT
Location: Delaware AB
* Title: Detection of AAV Vector DNA and Transgene RNA in Liver Tissue by
Fluorescent In Situ Hybridization (Poster 567).
Poster Session Title: AAV Vectors III
Session Date and Time: Friday, May 12, 2017, 5:45 - 7:45 p.m. EDT
Location: Hall A&B South
Investor and Analyst Breakfast
uniQure management will host an investor and analyst breakfast meeting featuring
members of the research and development team to review the data presented during
ASGCT.
Date and Time: Friday, May 12, 2017 at 7:00 am EDT
Omni Shoreham Hotel, The Congressional Room, 2500 Calvert
Location: Street NW, Washington, DC.
The Omni Shoreham hotel is located directly across the
conference venue.
To request attendance at the meeting, please RSVP to Investors(at)uniQure.com by
May 5, 2017, as space is limited.
About uniQure
uniQure is delivering on the promise of gene therapy - single treatments with
potentially curative results. We are leveraging our modular and validated
technology platform to rapidly advance a pipeline of proprietary and partnered
gene therapies to treat patients with liver/metabolic, central nervous system
and cardiovascular diseases. www.uniQure.com
uniQure Forward-Looking Statements
This press release contains forward-looking statements. All statements other
than statements of historical fact are forward-looking statements, which are
often indicated by terms such as "anticipate," "believe," "could," "estimate,"
"expect," "goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar expressions.
Forward-looking statements are based on management's beliefs and assumptions and
on information available to management only as of the date of this press
release. These forward-looking statements include, but are not limited to,
statements regarding the development of our gene therapy product candidates.
Our actual results could differ materially from those anticipated in these
forward-looking statements for many reasons, including, without limitation,
risks associated with collaboration arrangements, our and our collaborators'
clinical development activities, regulatory oversight, product commercialization
and intellectual property claims, as well as the risks, uncertainties and other
factors described under the heading "Risk Factors" in uniQure's 2016 Annual
Report on Form 10-K filed with the Securities and Exchange Commission on March
15, 2017. Given these risks, uncertainties and other factors, you should not
place undue reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new information
becomes available in the future.
uniQure Contacts:
Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452
m.cantor(at)uniQure.com
Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
e.mulder(at)uniQure.com
Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541
t.malone(at)uniQure.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: uniQure N.V. via GlobeNewswire
Datum: 24.04.2017 - 22:05 Uhr
Sprache: Deutsch
News-ID 537963
Anzahl Zeichen: 7317
contact information:
Town:
Amsterdam
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 149 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)"
steht unter der journalistisch-redaktionellen Verantwortung von
uniQure N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
